• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

Categorical Exclusion under 21 CFR 25.31(c)

Food and Drug Administration
Center for Biologics Evaluation and Research
Office of Compliance and Biologics Quality
Division of Manufacturing and Product Quality

To: NDA STN BN070012
From: Janie Russell, HFM-676
Subject: Categorical Exclusion under 21 CFR 25.31(c)
Date: July 27, 2007

I have reviewed pertinent sections of the New Drug Application (STN BN070012) from Fresnius Kabi for the manufacture of 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride infusion (Voluven), a plasma substitute for the treatment of hypovolemia, and find that the request for a categorical exclusion from an environmental assessment under 21 CFR 25.31(c) is justified because the product is composed of naturally occurring substances, the manufacture or use of the drug (plasma substitute) will not alter significantly the concentration or distribution of the substance, its metabolites or degradation products, and no extraordinary circumstances exist. This determination applies to all manufacturing locations associated with this application.

08/31/07 /Janie Russell/
Janie Russel
Committee Facility reviewer for the BLA
Concurrence:  
  /John A. Eltermann, Jr., R.Ph., M.S./
John A. Eltermann, Jr., R.Ph., M.S.
Director
Division of Manufacturing and Product Quality

 

 

Contact FDA

(800) 835-4709
(301) 827-1800
Consumer Affairs Branch (CBER)

Division of Communication and Consumer Affairs

Office of Communication, Outreach and Development

Food and Drug Administration

1401 Rockville Pike

Suite 200N/HFM-47

Rockville, MD 20852-1448